IFP Advisors’s PTC Therapeutics PTCT Stock Holding History

IFP Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$64.3K	Sell	788 -534	-40%	-$38.6K	﹤0.01%	2243
2026 Q1	$90.1K	Buy	1,322 +65	+5%	+$4.6K	﹤0.01%	1911
2025 Q4	$95.5K	Buy	1,257 +492	+64%	+$35.8K	﹤0.01%	1823
2025 Q3	$46.9K	Buy	765 +310	+68%	+$16.1K	﹤0.01%	2102
2025 Q2	$22.2K	Buy	455 +447	+5,588%	+$21.2K	﹤0.01%	2490
2025 Q1	$408	Hold	8	–	–	﹤0.01%	3505
2024 Q4	$361	Buy	+8	New	+$342	﹤0.01%	3505
2022 Q1	–	Sell	-28	Closed	-$1K	–	4583
2021 Q4	$1K	Buy	+28	New	+$1.07K	﹤0.01%	3088
2018 Q3	–	Sell	-15	Closed	-$1K	–	3983
2018 Q2	$1K	Hold	15	–	–	﹤0.01%	3757
2018 Q1	$0	Hold	15	–	–	﹤0.01%	3816
2017 Q4	$0	Sell	15 -81	-84%	-$1.37K	﹤0.01%	4049
2017 Q3	$2K	Hold	96	–	–	﹤0.01%	3778
2017 Q2	$2K	Buy	96 +80	+500%	+$1.08K	﹤0.01%	3758
2017 Q1	$0	Hold	16	–	–	﹤0.01%	4101
2016 Q4	$0	Hold	16	–	–	﹤0.01%	4101
2016 Q3	$0	Hold	16	–	–	﹤0.01%	4008
2016 Q2	$0	Buy	+16	New	+$117	﹤0.01%	4019

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

IFP Advisors's PTCT Position: Q2 2026 in Review

IFP Advisors reduced its PTC Therapeutics (PTCT) stake by 40% in Q2 2026, selling an estimated $38.6K and leaving 788 shares worth $64.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2243.

IFP Advisors first reported a position in PTCT in Q2 2016 and has held it in 17 quarters since. The position peaked at $95.5K in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

IFP Advisors held 788 shares of PTC Therapeutics worth $64.3K as of Q2 2026.
IFP Advisors sold 534 PTC Therapeutics shares in Q2 2026, an estimated $38.6K.
PTC Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2243 holding.
IFP Advisors first reported a position in PTC Therapeutics in Q2 2016 and has held it in 17 quarters since.
IFP Advisors's PTC Therapeutics position peaked at $95.5K in Q4 2025.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.